(Q38160737)

30 August 2017

title

Mechanisms of resistance to therapies targeting BRCA-mutant cancers (English)

1 reference

30 August 2017

1

1 reference

30 August 2017

2

Alan Ashworth

1 reference

30 August 2017

language of work or name

English

0 references

publication date

7 October 2013

1 reference

30 August 2017

1 reference

30 August 2017

volume

19

1 reference

30 August 2017

issue

11

1 reference

30 August 2017

page(s)

1381-1388

1 reference

https://scigraph.springernature.com/pub.10.1038/nm.3369

30 August 2017

exact match

0 references

cites work

Clonal evolution in cancer

1 reference

The emerging landscape of breast cancer susceptibility

21 January 2018

1 reference

Integrated genomic analyses of ovarian carcinoma

21 January 2018

1 reference

Integrating genetic approaches into the discovery of anticancer drugs

21 January 2018

1 reference

The concept of synthetic lethality in the context of anticancer therapy

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

21 January 2018

1 reference

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval

21 January 2018

1 reference

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers

21 January 2018

1 reference

The DNA damage response and cancer therapy

21 January 2018

1 reference

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers

21 January 2018

1 reference

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

21 January 2018

1 reference

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer

21 January 2018

1 reference

PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma

21 January 2018

1 reference

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

21 January 2018

1 reference

Resistance to therapy caused by intragenic deletion in BRCA2

21 January 2018

1 reference

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance

21 January 2018

1 reference

Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

21 January 2018

1 reference

6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance

21 January 2018

1 reference

A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency

21 January 2018

1 reference

BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair

21 January 2018

1 reference

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

21 January 2018

1 reference

Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors

21 January 2018

1 reference

53BP1 regulates DSB repair using Rif1 to control 5' end resection

21 January 2018

1 reference

Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching

21 January 2018

1 reference

RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection.

21 January 2018

1 reference

A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice

21 January 2018

1 reference

RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.

21 January 2018

1 reference

53BP1 expression in sporadic and inherited ovarian carcinoma: Relationship to genetic status and clinical outcomes.

21 January 2018

1 reference

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

21 January 2018

1 reference

Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors

21 January 2018

1 reference

Role of poly(ADP-ribose) formation in DNA repair

21 January 2018

1 reference

BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of Poly (ADP-Ribose) polymerase: an issue of potency

21 January 2018

1 reference

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity

21 January 2018

1 reference

Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.

21 January 2018

1 reference

Acquired resistance to combination treatment with temozolomide and ABT-888 is mediated by both base excision repair and homologous recombination DNA repair pathways

21 January 2018

1 reference

Poly(ADP-ribose) polymerase is hyperactivated in homologous recombination-defective cells

21 January 2018

1 reference

BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance.

21 January 2018

1 reference

A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer

21 January 2018

1 reference

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

21 January 2018

1 reference

Principles of cancer therapy: oncogene and non-oncogene addiction

21 January 2018

1 reference

Evolutionary plasticity of genetic interaction networks

21 January 2018

1 reference

The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer

21 January 2018

1 reference

Functional viability profiles of breast cancer

21 January 2018

1 reference

Secondary mutations inBRCA2associated with clinical resistance to a PARP inhibitor

21 January 2018

1 reference

Genetic Interactions in Cancer Progression and Treatment

21 January 2018

1 reference

12 December 2020

Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition

1 reference

12 December 2020

Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

1 reference

12 December 2020

Genetic reversion in an acute myelogenous leukemia cell line from a Fanconi anemia patient with biallelic mutations in BRCA2

1 reference

12 December 2020

Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer

1 reference

12 December 2020

ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development.

1 reference

12 December 2020

Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NM.3369

1 reference

30 August 2017

1 reference